Bayer's FDA Win and Neste Deal Land Days Before a Monsanto Hearing That Could Reset the Story

Bayer's sevabertinib cleared for first-line HER2-mutated NSCLC and a Neste canola deal signed, yet the September 14 glyphosate hearing caps the stock.

Bayer packed a week's worth of news into a single Wednesday. The FDA handed the German group's cancer drug Hyrnuo, known by its active ingredient sevabertinib, an accelerated first-line approval for adults with HER2-mutated non-small cell lung cancer. The same day, Bayer finalized a commercial agreement with Finnish energy firm Neste to scale up winter canola as a biofuel feedstock across the US Southern Great Plains.

Both announcements arrived with a hard deadline hanging over the stock: a hearing in the Monsanto/glyphosate litigation set for September 14, plus a separately scheduled settlement hearing. That collision of operational momentum and legal uncertainty has turned Bayer into a two-clock story — near-term sentiment driven by the courtroom, medium-term value pinned to the pharma pipeline.

What the FDA Actually Cleared

Until now, sevabertinib had been available in the US only after prior treatment, having won approval in November 2025. The new label lets physicians prescribe it to adults with locally advanced or metastatic HER2-mutated NSCLC without requiring an earlier systemic therapy.

The accelerated green light rests on the Phase I/II SOHO-01 trial, which produced a 75% overall response rate — 6% complete responses and 70% partial responses. Responses held for at least six months in 73% of patients. A confirmatory Phase III study, SOHO-02, is already underway.

Strategically, the first-line indication widens the addressable population considerably, since most patients previously reached sevabertinib only after other regimens failed. Oncology sits inside Bayer as a growth engine alongside the higher-margin but cyclical crop science business.

Biofuel Bet Targets a Market Set to Nearly Triple

The Neste tie-up centers on Bayer's "newgold" hybrid winter canola, which the partners intend to scale commercially as a feedstock for renewable diesel and sustainable aviation fuel. Bayer, the US Energy Information Administration and McKinsey project global biofuel demand will nearly triple to roughly 40 billion gallons by 2040.

The newgold hybrids are slated for market launch in autumn 2027, carrying winter hardiness along with Bayer's proprietary TruFlex technology and pod-shatter resistance. The crop also yields a protein-rich byproduct suitable for dairy, beef, poultry and swine feed.

Separately, Bayer disclosed the start of a Phase II trial of a GIRK4 inhibitor targeting atrial fibrillation — a third pipeline thread running alongside the oncology and biofuel news.

Two Analyst Houses, One Direction

Barclays raised its price target on Tuesday to EUR 70 from EUR 60, keeping an Overweight rating — a signal that at least one desk values the combination of approval momentum and balance-sheet progress well above the current share price.

Deutsche Bank Research struck a more measured tone the same week, reaffirming Buy with an unchanged EUR 60 target. Analyst Virginie Boucher-Ferte pointed to an investor event where Bayer laid out its five-year Crop Science targets in far greater detail, though without revising them. Her chief concern remains the cyclical nature of the agricultural chemicals business; other risk factors, in her view, have largely dissipated.

The stock closed Thursday at EUR 48.51, down 1.3% on the prior session, and sits just below its 50-day moving average of EUR 48.67 — a sign that short-term momentum has stalled.

Why Good News Isn't Moving the Needle

Over the past seven sessions, the shares have drifted 0.7% lower despite the run of approvals. That disconnect tells its own story: the market is weighting legal uncertainty more heavily than operational wins.

The September 14 hearing is a procedural step, not a resolution. Neither a ruling nor a settlement is guaranteed that day. If the process drags on or the outcome disappoints, the litigation overhang stays in place as a valuation cap, no matter how strong the pharma headlines get.

There is also a pipeline caveat. A hoped-for Japanese approval of Kerendia for non-diabetic kidney disease, and further pipeline milestones, remain announcements rather than completed achievements. A setback on any of them would quickly take the shine off the bull case.

The Bull Path

If the approval streak continues — a positive Japanese decision on Kerendia would be the next marker — the argument for a structurally undervalued pharma business gains weight. Should September 14 also point toward a settlement framework that narrows rather than extends the legal exposure, the stock could shed more of its litigation discount.

The shares have already climbed 88% off their 52-week low, a recovery that provides a base on which further confidence could build.

The Bear Path

The risk sits in the gap between court timelines and capital-market expectations. A drawn-out proceeding, or an adverse result, keeps the legal weight as a price ceiling regardless of pharma news flow. And with the market's muted reaction to recent wins, the burden of proof now falls on the pipeline to deliver completed successes rather than promising ones.

What September 14 Really Decides

The hearing is best read not as an endpoint but as a directional signal. If the pharma pipeline keeps producing approvals and the courtroom delivers no fresh escalation, Bayer's recovery path can extend — helped along by Barclays' freshly lifted target. If instead the litigation lengthens or settlement progress stays out of reach, the recent softness is more likely to persist than reverse.

Either way, the date marks the next concrete test of how the balance between opportunity and risk shifts in the weeks ahead.